← All trials
NCT04414241
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Sep 30, 2020
- Completion date
- Oct 31, 2020
- First posted
- Jun 3, 2020
- Last posted
- Jun 3, 2020
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cayetano Heredia UniversityLead sponsor
- Cayetano Heredia UniversityOverall official - principal investigator
- Cayetano Heredia UniversityStudy chair
- Instituto de Nacional de SaludStudy chair
- U.S. Naval Medical Research Unit SixStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.